OpenAI acquired Orchestra Bio, a four-year-old San Francisco startup whose AI agents help biopharma companies manage drug development programs, for undisclosed terms. Scientists and program leaders hand Orchestra’s agents the job of monitoring studies, and when one piece of a program slips, such as a failed manufacturing batch that pushes back a clinical trial, the agents work out which other timelines are affected and compare possible responses. OpenAI is moving Orchestra’s team and software into Rosalind, its life sciences unit built around GPT-Rosalind, a biology and chemistry model released in April. Rosalind’s tools have so far focused on research, like analyzing results and planning experiments, while Orchestra covers the coordination needed to turn a finding into a medicine.
